The pill formulation of zanubrutinib (Brukinsa; BeOne) is currently permitted for all five indications throughout various hematological cancers.Contrary to traditional drugs that involve elimination from the human body, Lenmeldy does not must be eliminated. Biodistribution experiments have revealed that Lenmeldy is dispersed to hematopoietic tissue… Read More